More on these below
The biology is complex, and that GLP-1 receptor in the body is not only controlling one thing or doing one thing, but has an intricate web of various effects. This article is exclusive to STAT+ subscribers Unlock this article plus in-depth analysis, newsletters, premium events, and news alerts
If considering a dose reduction for maintenance: Wait until weight has stabilized for at least 4 weeks at your current dose Reduce by one dose step (e.g., 12mg to 8mg), do not jump multiple steps Monitor weight closely for 8 weeks after the reduction If weight begins to increase, return to the previous maintenance dose The phase 3 trials specifically tested 4mg as a maintenance dose, suggesting Lilly sees viability in lower maintenance doses What happens if you stop Weight regain after discontinuing GLP-1 agonists is well documented with semaglutide and tirzepatide
If the medication is not stored correctly, it can be damaged or become unsafe to use
Multiple cardiovascular outcome trials (ELIXAlixisenatide, LEADERliraglutide, SUSTAIN-6semaglutide, EXSCELexenatide, Harmony Outcomesalbiglutide, REWINDdulaglutide, and PIONEER-6oral semaglutide) have reported, to a greater or lesser extent, improvements in cardiovascular outcomes, with a systematic review and meta-analysis of these trials involving a combined total of 56,004 participants showing that these drugs as a class reduced major adverse cardiovascular events by 12%, death from cardiovascular causes by 12%, fatal or nonfatal stroke by 16%, and fatal or nonfatal myocardial infarction by 9%
"While your body naturally produces GLP-1, some people may benefit from medications that mimic its effects." That's where injectables like Ozempic come in